CSL Behring
BiotechCSL Behring is a biotechnology company focused on Immunology, Neurology, Respiratory. Key products include Flucelvax, Flucelvax Quadrivalent.
FDA Novel Drug Designations
(2025)See 1 novel approval →
CSL Behring at a Glance
- Growing R&D activity with 15 trials in last 2 years
- Fast trial execution (27 months median completion)
CSL Behring's Key Drugs
CSL Behring's core commercial portfolio centers on ANDEMBRY, Corifact, Flucelvax, Flucelvax Quadrivalent, spanning Immunology and Neurology — its most strategically important drugs approved in the last 15 years.
CSL Behring's Recent FDA Approvals
CSL Behring secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
CSL Behring's Therapeutic Areas
CSL Behring's approved drugs and pipeline span 5 therapeutic areas, led by Immunology and Neurology, across 14 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CSL Behring's Top Competitors
CSL Behring's closest competitors by therapeutic-area and drug-target overlap include LEDERLE, Pfizer, and Novartis. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CSL Behring Pipeline Snapshot
CSL Behring has 23 active clinical programs from ClinicalTrials.gov — 5 Phase 3, 9 Phase 2 and 9 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ANDEMBRY leads revenue
- • 5 key drugs tracked
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 29/42 completed
- • Speed: 27 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges